Merck
Trade Merck 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MRK
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other.
MRK Key Statistics
Stock Snapshot
Merck(MRK) stock is priced at $148.81, giving the company a market capitalization of 368.05B. It carries a P/E multiple of 121.65 and pays a dividend yield of 2.21%.
During the trading session on 2026-08-20, Merck(MRK) shares reached a daily high of $152.52 and a low of $148.52. At a current price of $148.81, the stock is +0.2% higher than the low and still -2.4% under the high.
Trading activity shows a volume of 15.94M, compared to an average daily volume of 10.45M.
The stock's 52-week range extends from a low of $77.58 to a high of $153.50.
The stock's 52-week range extends from a low of $77.58 to a high of $153.50.
MRK News
Technology Moderna's Cancer Vaccine: Are Investors Putting The Cart Before The Horse? Licensing Messenger RNA companies collectively added $92 billion to their...
Merck & Co. (MRK), a U.S. pharmaceutical firm, got a major boost on Thursday, August 20, after investment banks Morgan Stanley (MS), UBS (UBS) and Goldman Sachs...
Moderna Plunges 20% One Day After Cancer Vaccine Breakthrough Sent Shares Up 177% By Thomas Richmond Published Aug 20, 12:22PM EDT Quick Read Moderna (MRNA) s...
Analyst ratings
68%
of 31 ratingsMore MRK News
...
Moderna Sinks 18% After 177% Cancer Vaccine Rally, BioNTech Falls 4%, Merck Slips By David Moadel Published Aug 20, 11:23AM EDT Quick Read Moderna (MRNA) drop...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as...
We wouldn't blame Merck & Co., Inc. ( ) shareholders if they were a little worried about the fact that Richard DeLuca, the Executive VP & President of Merck Ani...
UBS raised the firm’s price target on Merck (MRK) to $175 from $145 and keeps a Buy rating on the shares. Moderna (MRNA) and Merck surged 176% and 12%, respecti...
RBC Capital analyst Trung Huynh downgraded Merck (MRK) to Sector Perform from Outperform with a price target of $150, up from $142. Merck’s cancer vaccine data...
Shares of Moderna (MRNA +176.97%) soared on Wednesday after the vaccine maker announced potentially game-changing progress in the fight against cancer. Landmark...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.